These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35598359)

  • 1. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
    Roubaud G; Özgüroğlu M; Penel N; Matsubara N; Mehra N; Kolinsky MP; Procopio G; Feyerabend S; Joung JY; Gravis G; Nishimura K; Gedye C; Padua C; Shore N; Thiery-Vuillemin A; Saad F; van Alphen R; Carducci MA; Desai C; Brickel N; Poehlein C; Del Rosario P; Fizazi K
    Eur J Cancer; 2022 Jul; 170():73-84. PubMed ID: 35598359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
    Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
    Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
    N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
    Saad F; Armstrong AJ; Oya M; Vianna K; Özgüroğlu M; Gedye C; Buchschacher GL; Lee JY; Emmenegger U; Navratil J; Virizuela JA; Salazar A; Maillet D; Uemura H; Kim J; Oscroft E; Barker L; Degboe A; Clarke NW
    Eur Urol Oncol; 2024 Dec; 7(6):1394-1402. PubMed ID: 38582650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
    Mateo J; Porta N; Bianchini D; McGovern U; Elliott T; Jones R; Syndikus I; Ralph C; Jain S; Varughese M; Parikh O; Crabb S; Robinson A; McLaren D; Birtle A; Tanguay J; Miranda S; Figueiredo I; Seed G; Bertan C; Flohr P; Ebbs B; Rescigno P; Fowler G; Ferreira A; Riisnaes R; Pereira R; Curcean A; Chandler R; Clarke M; Gurel B; Crespo M; Nava Rodrigues D; Sandhu S; Espinasse A; Chatfield P; Tunariu N; Yuan W; Hall E; Carreira S; de Bono JS
    Lancet Oncol; 2020 Jan; 21(1):162-174. PubMed ID: 31806540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    Hussain M; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Roubaud G; Özgüroğlu M; Kang J; Burgents J; Gresty C; Corcoran C; Adelman CA; de Bono J;
    N Engl J Med; 2020 Dec; 383(24):2345-2357. PubMed ID: 32955174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
    Matsubara N; Nishimura K; Kawakami S; Joung JY; Uemura H; Goto T; Kwon TG; Sugimoto M; Kato M; Wang SS; Pang ST; Chen CH; Fujita T; Nii M; Shen L; Dujka M; Hussain M; de Bono J
    Jpn J Clin Oncol; 2022 May; 52(5):441-448. PubMed ID: 35229141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
    Saad F; Clarke NW; Oya M; Shore N; Procopio G; Guedes JD; Arslan C; Mehra N; Parnis F; Brown E; Schlürmann F; Joung JY; Sugimoto M; Sartor O; Liu YZ; Poehlein C; Barker L; Del Rosario PM; Armstrong AJ
    Lancet Oncol; 2023 Oct; 24(10):1094-1108. PubMed ID: 37714168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
    Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
    J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study.
    Xie J; Guo H; Dong B; Chen W; Jin C; Xu Q; Ding L; Liu W; Dong S; Zhao T; Yu Y; Guo C; Yao X; Peng B; Yang B
    Eur Urol Oncol; 2024 Oct; 7(5):1088-1096. PubMed ID: 38458891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
    N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    Clarke NW; Armstrong AJ; Thiery-Vuillemin A; Oya M; Shore N; Loredo E; Procopio G; de Menezes J; Girotto G; Arslan C; Mehra N; Parnis F; Brown E; Schlürmann F; Joung JY; Sugimoto M; Virizuela JA; Emmenegger U; Navratil J; Buchschacher GL; Poehlein C; Harrington EA; Desai C; Kang J; Saad F
    NEJM Evid; 2022 Sep; 1(9):EVIDoa2200043. PubMed ID: 38319800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
    Hussain M; Kocherginsky M; Agarwal N; Adra N; Zhang J; Paller CJ; Picus J; Reichert ZR; Szmulewitz RZ; Tagawa ST; Kuzel TM; Bazzi LA; Daignault-Newton S; Whang YE; Dreicer R; Stephenson RD; Rettig MB; Shevrin D; Gerke T; Chinnaiyan AM; Antonarakis ES
    Clin Cancer Res; 2024 Oct; 30(19):4318-4328. PubMed ID: 39115414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
    Mehra N; Fizazi K; de Bono JS; Barthélémy P; Dorff T; Stirling A; Machiels JP; Bimbatti D; Kilari D; Dumez H; Buttigliero C; van Oort IM; Castro E; Chen HC; Di Santo N; DeAnnuntis L; Healy CG; Scagliotti GV
    Oncologist; 2022 Oct; 27(10):e783-e795. PubMed ID: 36124924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Robson ME; Tung N; Conte P; Im SA; Senkus E; Xu B; Masuda N; Delaloge S; Li W; Armstrong A; Wu W; Goessl C; Runswick S; Domchek SM
    Ann Oncol; 2019 Apr; 30(4):558-566. PubMed ID: 30689707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
    Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
    Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
    Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
    Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.